Dr. Vincent Fradet (MD, PhD, FRCSC) is an uro-oncologist with a focused clinical practice at CHU de Québec-Laval University. He completed his medical training at Université de Montréal with an MD and residency in urology. He pursued with 5 years of subspecialty and research training. He obtained his uro-oncology accreditation from the Society of Urologic Oncology at the University of California, in San Francisco (UCSF) and completed a PhD in Clinical Research/Epidemiolgy (University de Montréal). Dr. Fradet has been an Associate Professor at Laval University since 2009, and is a regular researcher at the Laval University Cancer Research Center and at INAF (Institute for Nutrition and functional Food).

Dr. Fradet’s research goal is to improve our understanding of the links between lifestyle factors, including dietary omega-3 fatty acids and exercise, quality of life parameters, inflammation, and oncogenic pathways in prostate cancer, to progressively develop personalized preventive and treatment strategies. To that end, Dr. Fradet has built a unique biobank of bio-samples, developed pre-clinical models (mouse and primary cells in culture) and is running some clinical studies. All the epidemiological, clinical, and molecular (translational) projects led by his team are focused on improving our understanding of the biological mechanisms and the impact on quality of life of prostate cancer, as well as on developing biomarkers (urinary, blood, epigenetics, molecular and/or cellular) to be used in future intervention studies to stratify or select and monitor patients.

L'Hôtel-Dieu de Québec
6, rue McMahon
0622
Québec, Québec
Canada G1R 2J6
+1 418-525-4444, extension 15568 ou 20414 ou 16848
+1 418-691-3154
Vincent.Fradet@crchudeque... vincent.fradet@fmed.ulava...

Latest news

Data not available

35 entries « ‹ 1 of 4 › »

Gotto G, Drachenberg DE, Chin J, Casey R, Fradet V, Sabbagh R, Shayegan B, Rendon RA, Danielson B, Camacho F, Zardan A, Plante R, Hew H, Chan K, Feifer A

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC.

Journal Article

Can Urol Assoc J, 2020, ISSN: 1911-6470.

Abstract | Links:

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Journal Article

Eur Urol Oncol, 3 (3), pp. 298-305, 2020, ISSN: 2588-9311.

Abstract | Links:

Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, Hamilton RJ, Davis MK, Karampatos S, Mian R, Delouya G, Fradet Y, Mukherjee S, Conen D, Chen-Tournoux A, Johnson C, Bessissow A, Dresser G, Hameed AK, Abdel-Qadir H, Sener A, Pal R, Devereaux PJ, Pinthus J, RADICAL PC Investigators

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.

Journal Article

J Urol, 203 (6), pp. 1109-1116, 2020, ISSN: 0022-5347.

Abstract | Links:

Moussa H, Nguile-Makao M, Robitaille K, Guertin MH, Allaire J, Pelletier JF, Moreel X, Gevariya N, Diorio C, Desmeules P, Tetu B, Lamarche B, Julien P, Fradet V

Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level.

Journal Article

Nutrients, 11 (7), 2019, ISSN: 2072-6643.

Abstract | Links:

Lavallee E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Journal Article

Eur Urol Focus, 5 (6), pp. 998-1006, 2019.

Abstract | Links:

Gevariya N, Besancon M, Robitaille K, Picard V, Diabate L, Alesawi A, Julien P, Fradet Y, Bergeron A, Fradet V

Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice.

Journal Article

Prostate, 79 (1), pp. 9-20, 2019, ISSN: 0270-4137.

Abstract | Links:

Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M

Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series.

Journal Article

Urol Oncol, 37 (5), pp. 300.e9-300.e15, 2019, ISSN: 1078-1439.

Abstract | Links:

Nguile-Makao M, Allard MA, Bairati I, Meyer F, Robitaille K, Fradet Y, Lacombe L, Pouliot F, Toren P, Duchesne T, Fradet V

Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy

Journal Article

Clin Oncol (Belmont), 4 , pp. 1638 (5 pages), 2019.

McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P

Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?

Journal Article

Clin Genitourin Cancer, 17 (6), pp. e1122-e1128, 2019, ISSN: 1558-7673.

Abstract | Links:

Theriault B, Marceau-Grimard M, Blais AS, Fradet V, Moore K, Cloutier J

Urology residents on call: Investigating the workload and relevance of calls.

Journal Article

Can Urol Assoc J, 12 (2), pp. E71-E75, 2018, ISSN: 1911-6470.

Abstract | Links:

35 entries « ‹ 1 of 4 › »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, Subvention, The W. Garfield Weston Foundation, Transformational Research, from 2020-06-01 to 2023-05-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF), Subvention, Fonds de recherche du Québec - Nature et technologies, Regroupements stratégiques NT, from 2017-04-01 to 2024-03-31
  • Nutrition, santé et société (NUTRISS), Subvention, Fonds de recherche du Québec - Santé, Nouveaux Centres et Instituts de recherche - Subventions régulières, from 2019-04-01 to 2024-03-31
  • Prebiotics to enhance immunotherapy response in bladder cancer, Subvention, The W. Garfield Weston Foundation, 2018 Proof-of-Principle Grant Call, from 2019-01-01 to 2020-12-31
  • Territorialiser les systèmes alimentaires : une révolution pour la planète et la santé durable, Subvention, Alliance santé Québec (AsQ), from 2020-04-01 to 2021-03-31
  • Toward nutritional and epigenomic interventions in prostate cancer prevention and management, Subvention, Instituts de recherche en santé du Canada, Fonctionnement: Subvention de promotion de l’impact - CCREES, from 2017-10-01 to 2020-09-30

Recently finished projects

  • (FRSQ 85605) Plateforme méthodologique du CRCEO (statistiques uro-oncologie) , Subvention, Fondation du CHU de Québec, from 2019-05-30 to 2020-05-29
  • Détresse et satisfactions face au processus informationnel et décisionnel lors d'un cancer de la prostate localisé, Subvention, Fondation de l'Université Laval, from 2017-02-01 to 2020-03-31
  • Impact of microbiota on prostate cancer: from gut to tumor microenvironment., Subvention, Centre hospitalier universitaire de Montréal, from 2018-12-01 to 2019-12-31
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., Subvention, Société de recherche sur le cancer, Compétition GRePEC (SRC/FRSQ/MDEIE), from 2012-10-01 to 2020-08-31
  • Plateforme méthodologique du Centre de Recherche Clinique et Evaluative en Oncoloie (CRCEO) uro-oncologie, Subvention, Fondation du CHU de Québec, from 2019-03-05 to 2020-03-04
  • Projet de recherche CaptoMD : Cancer de la prostate, Subvention, Fondation du CHU de Québec, from 2019-03-22 to 2020-03-21
  • Rôle du microbiote intestinal dans le cancer de la prostate, Subvention, Université Laval - Soutien à la recherche, from 2018-05-01 to 2019-04-30
Data provided by the Université Laval research projects registery